Werewolf Therapeutics Inc...

0.87
0.02 (1.83%)
At close: Apr 24, 2025, 12:12 PM
1.83%
Bid 0.87
Market Cap 39.21M
Revenue (ttm) 1.89M
Net Income (ttm) -70.52M
EPS (ttm) -1.63
PE Ratio (ttm) -0.54
Forward PE -0.56
Analyst Buy
Ask 0.88
Volume 29,350
Avg. Volume (20D) 258,540
Open 0.85
Previous Close 0.85
Day's Range 0.84 - 0.88
52-Week Range 0.59 - 6.89
Beta 0.48

About HOWL

Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated In...

Industry Biotechnology
Sector Healthcare
IPO Date Apr 30, 2021
Employees 46
Stock Exchange NASDAQ
Ticker Symbol HOWL
Full Company Profile

Analyst Forecast

According to 3 analyst ratings, the average rating for HOWL stock is "Buy." The 12-month stock price forecast is $8, which is an increase of 814.60% from the latest price.

Stock Forecasts

Next Earnings Release

Werewolf Therapeutics Inc. is scheduled to release its earnings on May 6, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription